Conference abstractPublished 3 Aug 2015
How to market generics and bio-similars in Saudi Arabia
Gulf Pharmaceutical Industries, UAE
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Kingdom of Saudi Arabia (KSA) is considered one of the most matured markets of the six Gulf Cooperation Council (GCC) member states with generic drug penetration, and as healthcare expenditure as a percentage of GDP is increasing (expected to be 5.16% by 2015), there is an opportunity for the generic market to grow. There are currently 24 manufacturers in KSA, with 11 more under registration. Some local trends discussed were the strategic partnerships local manufacturers have with multinationals, the increased capacity and expansion at local manufacturing as well as increased Contract Manufacturing (CMO) being done for foreign companies. While local KSA manufacturers do enjoy a majority generic drug market share, foreign drug companies are also entering KSA. There is a focus on increased share of distribution, increase in strategic alliances with local manufacturers, as well as an increase in the number of clinical trials being conducted in KSA for branded drugs. In general, the Saudi FDA (SFDA) regulations governing are very similar to FDA regulations, which guarantee the need for worldwide harmonization. Exceptions adopted to meet the specific needs for Saudi Arabia and GCC countries are of course considered. âÂ?Â?How to market generics and bio-similar in Saudi ArabiaâÂ? gives comprehensive aspects such as legal framework, provisions affecting generic/bio-similar development and commercialization, reference medicinal product/generic listing or catalogue, requirements for registration & registration/evaluation process, format and content of the application, labelling/product monographs, fees, pharmacovigilance/post marketing surveillance, pricing and reimbursement, prescription and supply, and advertisement/promotion.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmaceutical Regulatory Affairs: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Shalu Lalichan”
